<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690181</url>
  </required_header>
  <id_info>
    <org_study_id>205421</org_study_id>
    <secondary_id>2015-003094-15</secondary_id>
    <secondary_id>V98_06E1</secondary_id>
    <nct_id>NCT02690181</nct_id>
  </id_info>
  <brief_title>Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.</brief_title>
  <official_title>A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this extension study is the initial assessment of safety and immunogenicity
      of the second dose of GBS Trivalent Vaccine following the time interval that is close to the
      inter-pregnancy interval observed in the general population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2016</start_date>
  <completion_date type="Actual">November 2, 2016</completion_date>
  <primary_completion_date type="Actual">November 2, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 61</measure>
    <time_frame>At Day 61</time_frame>
    <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ia at Day 61 post-vaccination, as measured by Enzyme-linked immunosorbent Assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Antibody Concentrations of GBS Serotype Ib Above Pre-specified Thresholds - Day 61</measure>
    <time_frame>At Day 61</time_frame>
    <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ib at day 61 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of All Subjects With Antibody Concentrations of GBS Serotype III Above Pre-specified Thresholds - Day 61</measure>
    <time_frame>At Day 61</time_frame>
    <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype III at day 61 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numbers of Subjects With Solicited Local and Systemic Adverse Events (AEs)</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Threshold for Erythema, Swelling and Induration: None (0 mm), Any (&gt;= 1 mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Day 1 to Day 31</time_frame>
    <description>The number of subjects with any unsolicited AEs from the day of vaccination in study V98_06E1 to Day 31. An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject who has signed the informed consent. Potential unsolicited AEs may be medically attended (defined as symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider), or were of concern to the subject. Possibly Related AE definition: the administration of the investigational vaccine and AE are considered reasonably related in time and the AE could be explained by exposure to the investigational vaccine or by other causes. Probably Related AE definition: exposure to the investigational vaccine and AE are reasonably related in time and no alternative explanation has been identified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs), Medically Attended AEs, and AEs Leading to Study Withdrawal</measure>
    <time_frame>Day 1 to Day 181</time_frame>
    <description>An SAE is defined as any untoward medical occurrence that at any dose results in one or more of the following: Death; life-threatening; that does not refer to an event which hypothetically might have caused death if it were more severe; required or prolonged hospitalization; persistent or significant disability/incapacity; congenital anomaly/or birth defect; any important and significant medical event that may not be immediately life-threatening or resulting in death or hospitalization but, based upon appropriate medical judgement, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above. &quot;Medically attended adverse event&quot; is defined as an adverse event that leads to a visit to a healthcare provider and &quot;AEs leading to withdrawal&quot; are defined as adverse events leading to study or vaccine withdrawal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 31</measure>
    <time_frame>At Day 31</time_frame>
    <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ia at Day 31 post-vaccination, as measured by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Antibody Concentrations of GBS Serotype Ib Above Pre-specified Thresholds - Day 31</measure>
    <time_frame>At Day 31</time_frame>
    <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ib at day 31 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Antibody Concentrations of GBS Serotype III Above Pre-specified Thresholds - Day 31</measure>
    <time_frame>At Day 31</time_frame>
    <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype III at day 31 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia</measure>
    <time_frame>At Day 1, Day 31 and Day 61.</time_frame>
    <description>The Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in All Subjects were estimated for at Day 1, Day 31 and Day 61.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations of GBS Serotype Ib</measure>
    <time_frame>At Day 1, Day 31 and Day 61</time_frame>
    <description>The Geometric Mean Antibody Concentrations of GBS Serotype Ib in All Subjects were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations of GBS Serotype III</measure>
    <time_frame>At Day 1, Day 31 and Day 61</time_frame>
    <description>The Geometric Mean Antibody Concentrations of GBS Serotype III in All Subjects were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than the Lower Limit of Quantitation (LLQ)</measure>
    <time_frame>At Day 1, Day 31 and Day 61</time_frame>
    <description>The Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in subjects with prevaccination serotype-specific GBS antibody less than LLQ were estimated for at Day 1, Day 31 and Day 61.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations of GBS Serotype Ib in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than LLQ</measure>
    <time_frame>At Day 1, Day 31 and Day 61</time_frame>
    <description>The Geometric Mean Antibody Concentrations of GBS Serotype Ib in subjects with prevaccination serotype-specific GBS antibody less than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations of GBS Serotype III in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than LLQ</measure>
    <time_frame>At Day 1, Day 31 and Day 61</time_frame>
    <description>The Geometric Mean Antibody Concentrations of GBS Serotype III in subjects with prevaccination serotype-specific GBS antibody less than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ</measure>
    <time_frame>At Day 1, Day 31 and Day 61</time_frame>
    <description>The Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in subjects with prevaccination serotype-specific GBS antibody equal or greater than LLQ were estimated for at Day 1, Day 31 and Day 61.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations of GBS Serotype Ib in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ</measure>
    <time_frame>At Day 1, Day 31 and Day 61</time_frame>
    <description>The Geometric Mean Antibody Concentrations of GBS Serotype Ib in subjects with prevaccination serotype-specific GBS antibody equal or greater than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations of GBS Serotype III in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ</measure>
    <time_frame>At Day 1, Day 31 and Day 61</time_frame>
    <description>The Geometric Mean Antibody Concentrations of GBS Serotype III in subjects with prevaccination serotype-specific GBS antibody equal or greater than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean ELISA Anti-Diphtheria Antibody Concentrations in All Subjects</measure>
    <time_frame>At Day 1 (V98_06 or V98_06E1) and Day 61</time_frame>
    <description>Geometric Mean ELISA Anti-Diphtheria Antibody Concentrations (95%CI) in All Subjects at Day 1 Pre-vaccination in the V98_06 study or V98_06E1 for the Naive Group and at Day 61 Post-vaccination in Study V98_06E1. Anti-diphtheria antibody testing was not performed in this study because no diphtheria vaccine was administered in the study and also because data from other Cross Reactive Material(CRM)-based vaccines demonstrate that administration has not resulted in a decline in anti-diphtheria antibody concentrations.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Bacterial Infection Due to Streptococcus, Group B</condition>
  <arm_group>
    <arm_group_label>GBS NoAdj/GBS NoAdj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBS Alum/GBS NoAdj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBS MF59 Full/GBS NoAdj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBS MF59 Half/GBS NoAdj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/GBS NoAdj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had received placebo in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naive/GBS NoAdj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GBS Trivalent Vaccine</intervention_name>
    <description>Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .</description>
    <arm_group_label>GBS Alum/GBS NoAdj</arm_group_label>
    <arm_group_label>GBS MF59 Full/GBS NoAdj</arm_group_label>
    <arm_group_label>GBS MF59 Half/GBS NoAdj</arm_group_label>
    <arm_group_label>GBS NoAdj/GBS NoAdj</arm_group_label>
    <arm_group_label>Naive/GBS NoAdj</arm_group_label>
    <arm_group_label>Placebo/GBS NoAdj</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy, non-pregnant subjects who have received a single 5 µg dose of GBS Trivalent
             Vaccine or placebo in the V98_06 study and healthy non-pregnant female subjects aged
             22-46 years inclusive on the day of informed consent who have not received any GBS
             vaccine in the past

          2. Individuals in good health as determined by the outcome of medical history, physical
             examination and clinical judgment of the investigator

          3. Females of childbearing potential who are using an effective birth control method
             which they intend to use until the end of the study (day 181 visit) or females of
             non-childbearing potential

        Exclusion Criteria:

          1. Progressive, unstable or uncontrolled clinical conditions, or clinical conditions
             representing a contraindication to intramuscular vaccination and blood draws

          2. Abnormal function of the immune system

          3. Received immunoglobulins or any blood products within 180 days prior to informed
             consent

          4. Received an investigational or non-registered medicinal product within 30 days prior
             to informed consent

          5. Any other clinical condition that, in the opinion of the investigator, might interfere
             with the results of the study or pose additional risk to the subject due to
             participation in the study

          6. Individuals who received any other vaccines within 14 days for inactivated vaccines or
             28 days for live vaccines prior to enrolment in this study or who are planning to
             receive any vaccine within 28 days from the study vaccination. Exception - an
             inactivated influenza vaccine may be administered up to 7 days prior to study
             vaccination or 7 days after study vaccination

          7. Individuals who anticipate becoming pregnant prior to the end of the study, or
             individuals who are breastfeeding

          8. Individuals who have had a previous immunization with a vaccine containing Group B
             Streptococcus antigens that was not part of V98_06 study

          9. Individuals with a fever (oral temperature ≥ 38°C) within 3 days prior to day 1 or use
             of antipyretics and/or analgesic medications within 24 hours prior to day 1

         10. Individuals with acute or chronic infection(s) that require systemic antibiotic
             treatment or antiviral therapy, within 7 days prior to day 1
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 16, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <results_first_submitted>October 30, 2017</results_first_submitted>
  <results_first_submitted_qc>May 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2018</results_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02690181/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 1 site in Belgium.</recruitment_details>
      <pre_assignment_details>All enrolled subjects completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GBS NoAdj/GBS NoAdj Group</title>
          <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="P2">
          <title>GBS Alum/GBS NoAdj Group</title>
          <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="P3">
          <title>GBS MF59 Half/GBS NoAdj Group</title>
          <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="P4">
          <title>GBS MF59 Full/GBS NoAdj Group</title>
          <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="P5">
          <title>Placebo/GBS NoAdj Group</title>
          <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="P6">
          <title>Naive/GBS NoAdj Group</title>
          <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GBS NoAdj/GBS NoAdj Group</title>
          <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="B2">
          <title>GBS Alum/GBS NoAdj Group</title>
          <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="B3">
          <title>GBS MF59 Half/GBS NoAdj Group</title>
          <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="B4">
          <title>GBS MF59 Full/GBS NoAdj Group</title>
          <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="B5">
          <title>Placebo/GBS NoAdj Group</title>
          <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="B6">
          <title>Naive/GBS NoAdj Group</title>
          <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="21"/>
            <count group_id="B7" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" spread="6.91"/>
                    <measurement group_id="B2" value="31.6" spread="6.06"/>
                    <measurement group_id="B3" value="28.9" spread="4.68"/>
                    <measurement group_id="B4" value="29.7" spread="6.22"/>
                    <measurement group_id="B5" value="28.3" spread="5.39"/>
                    <measurement group_id="B6" value="29.2" spread="6.96"/>
                    <measurement group_id="B7" value="30.1" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 61</title>
        <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ia at Day 61 post-vaccination, as measured by Enzyme-linked immunosorbent Assay (ELISA).</description>
        <time_frame>At Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 61</title>
          <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ia at Day 61 post-vaccination, as measured by Enzyme-linked immunosorbent Assay (ELISA).</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 0.1 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="47.8" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="83.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.2 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="47.8" upper_limit="100"/>
                    <measurement group_id="O6" value="95" lower_limit="75.1" upper_limit="99.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="47.8" upper_limit="100"/>
                    <measurement group_id="O6" value="90" lower_limit="68.3" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="80" lower_limit="28.4" upper_limit="99.5"/>
                    <measurement group_id="O6" value="85" lower_limit="62.1" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="60" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O6" value="65" lower_limit="40.8" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="93" lower_limit="68.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="90" lower_limit="55.5" upper_limit="99.75"/>
                    <measurement group_id="O5" value="60" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="93" lower_limit="68.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="90" lower_limit="55.5" upper_limit="99.75"/>
                    <measurement group_id="O5" value="60" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 8 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="64" upper_limit="99.81"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="93" lower_limit="68.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="90" lower_limit="55.5" upper_limit="99.75"/>
                    <measurement group_id="O5" value="60" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Antibody Concentrations of GBS Serotype Ib Above Pre-specified Thresholds - Day 61</title>
        <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ib at day 61 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
        <time_frame>At Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Antibody Concentrations of GBS Serotype Ib Above Pre-specified Thresholds - Day 61</title>
          <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ib at day 61 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.in this study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 0.1 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="47.8" upper_limit="100"/>
                    <measurement group_id="O6" value="85" lower_limit="62.1" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.2 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="47.8" upper_limit="100"/>
                    <measurement group_id="O6" value="80" lower_limit="56.3" upper_limit="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="80" lower_limit="28.4" upper_limit="99.5"/>
                    <measurement group_id="O6" value="70" lower_limit="45.7" upper_limit="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="60" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O6" value="65" lower_limit="40.8" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="60" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O6" value="50" lower_limit="27.2" upper_limit="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="93" lower_limit="66.1" upper_limit="99.82"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="60" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O6" value="50" lower_limit="27.2" upper_limit="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="54.6" upper_limit="98.1"/>
                    <measurement group_id="O2" value="93" lower_limit="66.1" upper_limit="99.82"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="60" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O6" value="45" lower_limit="23.1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 8 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="54.6" upper_limit="98.1"/>
                    <measurement group_id="O2" value="93" lower_limit="66.1" upper_limit="99.82"/>
                    <measurement group_id="O3" value="93" lower_limit="68.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="20" lower_limit="0.5" upper_limit="71.6"/>
                    <measurement group_id="O6" value="40" lower_limit="19.1" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of All Subjects With Antibody Concentrations of GBS Serotype III Above Pre-specified Thresholds - Day 61</title>
        <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype III at day 61 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
        <time_frame>At Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of All Subjects With Antibody Concentrations of GBS Serotype III Above Pre-specified Thresholds - Day 61</title>
          <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype III at day 61 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 0.1 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="47.8" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="83.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.2 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="47.8" upper_limit="100"/>
                    <measurement group_id="O6" value="80" lower_limit="56.3" upper_limit="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="80" lower_limit="28.4" upper_limit="99.5"/>
                    <measurement group_id="O6" value="80" lower_limit="56.3" upper_limit="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="40" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O6" value="75" lower_limit="50.9" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="40" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O6" value="65" lower_limit="40.8" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="40" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O6" value="65" lower_limit="40.8" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="40" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O6" value="50" lower_limit="27.2" upper_limit="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 8 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="92" lower_limit="64" upper_limit="99.81"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="40" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O6" value="50" lower_limit="27.2" upper_limit="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Numbers of Subjects With Solicited Local and Systemic Adverse Events (AEs)</title>
        <description>Threshold for Erythema, Swelling and Induration: None (0 mm), Any (&gt;= 1 mm).</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>All screened subjects who signed informed consent form, provided demographic data and/or baseline screening assessments, were randomized and assigned a study subject ID, received the study vaccination and with any solicited adverse event data and/or indicators of solicited adverse events (e.g., use of analgesics/antipyretics).</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Subjects With Solicited Local and Systemic Adverse Events (AEs)</title>
          <description>Threshold for Erythema, Swelling and Induration: None (0 mm), Any (&gt;= 1 mm).</description>
          <population>All screened subjects who signed informed consent form, provided demographic data and/or baseline screening assessments, were randomized and assigned a study subject ID, received the study vaccination and with any solicited adverse event data and/or indicators of solicited adverse events (e.g., use of analgesics/antipyretics).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warmth</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Myalgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Arthralgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38°C)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
        <description>The number of subjects with any unsolicited AEs from the day of vaccination in study V98_06E1 to Day 31. An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject who has signed the informed consent. Potential unsolicited AEs may be medically attended (defined as symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider), or were of concern to the subject. Possibly Related AE definition: the administration of the investigational vaccine and AE are considered reasonably related in time and the AE could be explained by exposure to the investigational vaccine or by other causes. Probably Related AE definition: exposure to the investigational vaccine and AE are reasonably related in time and no alternative explanation has been identified.</description>
        <time_frame>Day 1 to Day 31</time_frame>
        <population>All screened subjects who signed informed consent form, provided demographic data and/or baseline screening assessments, were randomized and assigned a study subject ID, received the study vaccination and with any unsolicited adverse event data.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
          <description>The number of subjects with any unsolicited AEs from the day of vaccination in study V98_06E1 to Day 31. An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject who has signed the informed consent. Potential unsolicited AEs may be medically attended (defined as symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider), or were of concern to the subject. Possibly Related AE definition: the administration of the investigational vaccine and AE are considered reasonably related in time and the AE could be explained by exposure to the investigational vaccine or by other causes. Probably Related AE definition: exposure to the investigational vaccine and AE are reasonably related in time and no alternative explanation has been identified.</description>
          <population>All screened subjects who signed informed consent form, provided demographic data and/or baseline screening assessments, were randomized and assigned a study subject ID, received the study vaccination and with any unsolicited adverse event data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly or probably related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs), Medically Attended AEs, and AEs Leading to Study Withdrawal</title>
        <description>An SAE is defined as any untoward medical occurrence that at any dose results in one or more of the following: Death; life-threatening; that does not refer to an event which hypothetically might have caused death if it were more severe; required or prolonged hospitalization; persistent or significant disability/incapacity; congenital anomaly/or birth defect; any important and significant medical event that may not be immediately life-threatening or resulting in death or hospitalization but, based upon appropriate medical judgement, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above. &quot;Medically attended adverse event&quot; is defined as an adverse event that leads to a visit to a healthcare provider and &quot;AEs leading to withdrawal&quot; are defined as adverse events leading to study or vaccine withdrawal.</description>
        <time_frame>Day 1 to Day 181</time_frame>
        <population>All screened subjects who signed informed consent form, provided demographic data and/or baseline screening assessments, were randomized and assigned a study subject ID, received the study vaccination and with any unsolicited adverse event data.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs), Medically Attended AEs, and AEs Leading to Study Withdrawal</title>
          <description>An SAE is defined as any untoward medical occurrence that at any dose results in one or more of the following: Death; life-threatening; that does not refer to an event which hypothetically might have caused death if it were more severe; required or prolonged hospitalization; persistent or significant disability/incapacity; congenital anomaly/or birth defect; any important and significant medical event that may not be immediately life-threatening or resulting in death or hospitalization but, based upon appropriate medical judgement, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above. &quot;Medically attended adverse event&quot; is defined as an adverse event that leads to a visit to a healthcare provider and &quot;AEs leading to withdrawal&quot; are defined as adverse events leading to study or vaccine withdrawal.</description>
          <population>All screened subjects who signed informed consent form, provided demographic data and/or baseline screening assessments, were randomized and assigned a study subject ID, received the study vaccination and with any unsolicited adverse event data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 31</title>
        <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ia at Day 31 post-vaccination, as measured by ELISA.</description>
        <time_frame>At Day 31</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 31</title>
          <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ia at Day 31 post-vaccination, as measured by ELISA.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 0.1 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="54.1" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="83.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.2 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="54.1" upper_limit="100"/>
                    <measurement group_id="O6" value="85" lower_limit="62.1" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="54.1" upper_limit="100"/>
                    <measurement group_id="O6" value="80" lower_limit="56.3" upper_limit="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="83" lower_limit="35.9" upper_limit="99.58"/>
                    <measurement group_id="O6" value="75" lower_limit="50.9" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="67" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="67" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="93" lower_limit="68.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="90" lower_limit="55.5" upper_limit="99.75"/>
                    <measurement group_id="O5" value="67" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 8 µg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="93" lower_limit="68.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="90" lower_limit="55.5" upper_limit="99.75"/>
                    <measurement group_id="O5" value="67" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Antibody Concentrations of GBS Serotype Ib Above Pre-specified Thresholds - Day 31</title>
        <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ib at day 31 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
        <time_frame>At Day 31</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Antibody Concentrations of GBS Serotype Ib Above Pre-specified Thresholds - Day 31</title>
          <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype Ib at day 31 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 0.1 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="54.1" upper_limit="100"/>
                    <measurement group_id="O6" value="75" lower_limit="50.9" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.2 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="54.1" upper_limit="100"/>
                    <measurement group_id="O6" value="70" lower_limit="45.7" upper_limit="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="83" lower_limit="35.9" upper_limit="99.58"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="83" lower_limit="35.9" upper_limit="99.58"/>
                    <measurement group_id="O6" value="45" lower_limit="23.1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="50" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O6" value="45" lower_limit="23.1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="93" lower_limit="66.1" upper_limit="99.82"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="50" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O6" value="45" lower_limit="23.1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="64" upper_limit="99.81"/>
                    <measurement group_id="O2" value="93" lower_limit="66.1" upper_limit="99.82"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="50" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O6" value="45" lower_limit="23.1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 8 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="54.6" upper_limit="98.1"/>
                    <measurement group_id="O2" value="93" lower_limit="66.1" upper_limit="99.82"/>
                    <measurement group_id="O3" value="93" lower_limit="68.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="50" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O6" value="45" lower_limit="23.1" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Antibody Concentrations of GBS Serotype III Above Pre-specified Thresholds - Day 31</title>
        <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype III at day 31 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
        <time_frame>At Day 31</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Antibody Concentrations of GBS Serotype III Above Pre-specified Thresholds - Day 31</title>
          <description>Percentage of subjects who reach pre-defined sequential serotype-specific serum antibody levels for serotype III at day 31 post-vaccination. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 0.1 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="54.1" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="83.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.2 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="67" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O6" value="75" lower_limit="50.9" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 0.5 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="67" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O6" value="70" lower_limit="45.7" upper_limit="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="50" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O6" value="65" lower_limit="40.8" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="50" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O6" value="60" lower_limit="36.1" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 3 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="33" lower_limit="4.3" upper_limit="77.7"/>
                    <measurement group_id="O6" value="55" lower_limit="31.5" upper_limit="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="33" lower_limit="4.3" upper_limit="77.7"/>
                    <measurement group_id="O6" value="55" lower_limit="31.5" upper_limit="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 8 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                    <measurement group_id="O2" value="92" lower_limit="64" upper_limit="99.81"/>
                    <measurement group_id="O3" value="100" lower_limit="78.2" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="69.2" upper_limit="100"/>
                    <measurement group_id="O5" value="33" lower_limit="4.3" upper_limit="77.7"/>
                    <measurement group_id="O6" value="50" lower_limit="27.2" upper_limit="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia</title>
        <description>The Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in All Subjects were estimated for at Day 1, Day 31 and Day 61.</description>
        <time_frame>At Day 1, Day 31 and Day 61.</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia</title>
          <description>The Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in All Subjects were estimated for at Day 1, Day 31 and Day 61.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia - Day 1 (V98_06E1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.32" lower_limit="3.03" upper_limit="29"/>
                    <measurement group_id="O2" value="5.50" lower_limit="1.79" upper_limit="17"/>
                    <measurement group_id="O3" value="3.44" lower_limit="1.16" upper_limit="10"/>
                    <measurement group_id="O4" value="2.18" lower_limit="0.58" upper_limit="8.24"/>
                    <measurement group_id="O5" value="1.05" lower_limit="0.19" upper_limit="5.86"/>
                    <measurement group_id="O6" value="0.32" lower_limit="0.13" upper_limit="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia - Day 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.13" lower_limit="23" upper_limit="165"/>
                    <measurement group_id="O2" value="81.61" lower_limit="31" upper_limit="213"/>
                    <measurement group_id="O3" value="64.19" lower_limit="25" upper_limit="162"/>
                    <measurement group_id="O4" value="57.54" lower_limit="19" upper_limit="179"/>
                    <measurement group_id="O5" value="19.25" lower_limit="4.46" upper_limit="83"/>
                    <measurement group_id="O6" value="10.06" lower_limit="4.52" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia - Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.53" lower_limit="21" upper_limit="129"/>
                    <measurement group_id="O2" value="65.30" lower_limit="27" upper_limit="158"/>
                    <measurement group_id="O3" value="44.69" lower_limit="19" upper_limit="105"/>
                    <measurement group_id="O4" value="50.67" lower_limit="18" upper_limit="145"/>
                    <measurement group_id="O5" value="21.36" lower_limit="4.85" upper_limit="94"/>
                    <measurement group_id="O6" value="10.02" lower_limit="4.77" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentrations of GBS Serotype Ib</title>
        <description>The Geometric Mean Antibody Concentrations of GBS Serotype Ib in All Subjects were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
        <time_frame>At Day 1, Day 31 and Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations of GBS Serotype Ib</title>
          <description>The Geometric Mean Antibody Concentrations of GBS Serotype Ib in All Subjects were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.093" upper_limit="0.41"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.073" upper_limit="0.32"/>
                    <measurement group_id="O3" value="0.10" lower_limit="0.049" upper_limit="0.20"/>
                    <measurement group_id="O4" value="0.16" lower_limit="0.068" upper_limit="0.39"/>
                    <measurement group_id="O5" value="0.14" lower_limit="0.035" upper_limit="0.55"/>
                    <measurement group_id="O6" value="0.17" lower_limit="0.093" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.62" lower_limit="28" upper_limit="232"/>
                    <measurement group_id="O2" value="74.96" lower_limit="27" upper_limit="207"/>
                    <measurement group_id="O3" value="89.59" lower_limit="33" upper_limit="241"/>
                    <measurement group_id="O4" value="85.90" lower_limit="26" upper_limit="286"/>
                    <measurement group_id="O5" value="6.61" lower_limit="0.99" upper_limit="44"/>
                    <measurement group_id="O6" value="3.55" lower_limit="1.52" upper_limit="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.32" lower_limit="22" upper_limit="145"/>
                    <measurement group_id="O2" value="57.82" lower_limit="23" upper_limit="143"/>
                    <measurement group_id="O3" value="59.13" lower_limit="24" upper_limit="143"/>
                    <measurement group_id="O4" value="65.53" lower_limit="22" upper_limit="192"/>
                    <measurement group_id="O5" value="5.51" lower_limit="1.01" upper_limit="30"/>
                    <measurement group_id="O6" value="4.47" lower_limit="2.09" upper_limit="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentrations of GBS Serotype III</title>
        <description>The Geometric Mean Antibody Concentrations of GBS Serotype III in All Subjects were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
        <time_frame>At Day 1, Day 31 and Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations of GBS Serotype III</title>
          <description>The Geometric Mean Antibody Concentrations of GBS Serotype III in All Subjects were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.20" upper_limit="0.82"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.085" upper_limit="0.36"/>
                    <measurement group_id="O3" value="0.25" lower_limit="0.13" upper_limit="0.49"/>
                    <measurement group_id="O4" value="0.17" lower_limit="0.076" upper_limit="0.39"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.040" upper_limit="0.54"/>
                    <measurement group_id="O6" value="0.31" lower_limit="0.17" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.30" lower_limit="42" upper_limit="294"/>
                    <measurement group_id="O2" value="104.55" lower_limit="40" upper_limit="277"/>
                    <measurement group_id="O3" value="109.23" lower_limit="44" upper_limit="269"/>
                    <measurement group_id="O4" value="216.39" lower_limit="71" upper_limit="655"/>
                    <measurement group_id="O5" value="2.66" lower_limit="0.46" upper_limit="15"/>
                    <measurement group_id="O6" value="5.33" lower_limit="2.43" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.30" lower_limit="39" upper_limit="214"/>
                    <measurement group_id="O2" value="80.94" lower_limit="34" upper_limit="190"/>
                    <measurement group_id="O3" value="81.71" lower_limit="37" upper_limit="180"/>
                    <measurement group_id="O4" value="200.78" lower_limit="76" upper_limit="531"/>
                    <measurement group_id="O5" value="2.67" lower_limit="0.57" upper_limit="12"/>
                    <measurement group_id="O6" value="5.82" lower_limit="2.92" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than the Lower Limit of Quantitation (LLQ)</title>
        <description>The Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in subjects with prevaccination serotype-specific GBS antibody less than LLQ were estimated for at Day 1, Day 31 and Day 61.</description>
        <time_frame>At Day 1, Day 31 and Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than the Lower Limit of Quantitation (LLQ)</title>
          <description>The Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in subjects with prevaccination serotype-specific GBS antibody less than LLQ were estimated for at Day 1, Day 31 and Day 61.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia - Day 1 (V98_06E1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" lower_limit="0.43" upper_limit="4.27"/>
                    <measurement group_id="O2" value="2.59" lower_limit="0.99" upper_limit="6.75"/>
                    <measurement group_id="O3" value="0.81" lower_limit="0.30" upper_limit="2.24"/>
                    <measurement group_id="O4" value="1.12" lower_limit="0.36" upper_limit="3.52"/>
                    <measurement group_id="O5" value="0.45" lower_limit="0.099" upper_limit="2.05"/>
                    <measurement group_id="O6" value="0.16" lower_limit="0.074" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia - Day 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.25" lower_limit="8.59" upper_limit="121"/>
                    <measurement group_id="O2" value="62.54" lower_limit="21" upper_limit="189"/>
                    <measurement group_id="O3" value="35.47" lower_limit="11" upper_limit="114"/>
                    <measurement group_id="O4" value="46.11" lower_limit="12" upper_limit="173"/>
                    <measurement group_id="O5" value="6.34" lower_limit="1.10" upper_limit="36"/>
                    <measurement group_id="O6" value="3.98" lower_limit="1.61" upper_limit="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia - Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.33" lower_limit="8.12" upper_limit="85"/>
                    <measurement group_id="O2" value="49.01" lower_limit="18" upper_limit="131"/>
                    <measurement group_id="O3" value="24.89" lower_limit="8.82" upper_limit="70"/>
                    <measurement group_id="O4" value="39.56" lower_limit="12" upper_limit="128"/>
                    <measurement group_id="O5" value="5.79" lower_limit="0.96" upper_limit="35"/>
                    <measurement group_id="O6" value="4.25" lower_limit="1.90" upper_limit="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentrations of GBS Serotype Ib in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than LLQ</title>
        <description>The Geometric Mean Antibody Concentrations of GBS Serotype Ib in subjects with prevaccination serotype-specific GBS antibody less than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
        <time_frame>At Day 1, Day 31 and Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations of GBS Serotype Ib in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than LLQ</title>
          <description>The Geometric Mean Antibody Concentrations of GBS Serotype Ib in subjects with prevaccination serotype-specific GBS antibody less than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.078" lower_limit="0.078" upper_limit="0.078"/>
                    <measurement group_id="O2" value="0.078" lower_limit="0.078" upper_limit="0.078"/>
                    <measurement group_id="O3" value="0.078" lower_limit="0.078" upper_limit="0.078"/>
                    <measurement group_id="O4" value="0.078" lower_limit="0.078" upper_limit="0.078"/>
                    <measurement group_id="O5" value="0.078" lower_limit="0.078" upper_limit="0.078"/>
                    <measurement group_id="O6" value="0.078" lower_limit="0.078" upper_limit="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.78" lower_limit="20" upper_limit="182"/>
                    <measurement group_id="O2" value="69.05" lower_limit="22" upper_limit="220"/>
                    <measurement group_id="O3" value="53.01" lower_limit="21" upper_limit="134"/>
                    <measurement group_id="O4" value="65.50" lower_limit="19" upper_limit="224"/>
                    <measurement group_id="O5" value="1.47" lower_limit="0.20" upper_limit="11"/>
                    <measurement group_id="O6" value="0.79" lower_limit="0.32" upper_limit="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.59" lower_limit="15" upper_limit="111"/>
                    <measurement group_id="O2" value="47.71" lower_limit="16" upper_limit="138"/>
                    <measurement group_id="O3" value="34.12" lower_limit="15" upper_limit="80"/>
                    <measurement group_id="O4" value="47.58" lower_limit="15" upper_limit="147"/>
                    <measurement group_id="O5" value="1.32" lower_limit="0.21" upper_limit="8.37"/>
                    <measurement group_id="O6" value="1.19" lower_limit="0.52" upper_limit="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentrations of GBS Serotype III in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than LLQ</title>
        <description>The Geometric Mean Antibody Concentrations of GBS Serotype III in subjects with prevaccination serotype-specific GBS antibody less than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
        <time_frame>At Day 1, Day 31 and Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations of GBS Serotype III in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than LLQ</title>
          <description>The Geometric Mean Antibody Concentrations of GBS Serotype III in subjects with prevaccination serotype-specific GBS antibody less than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O4" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O6" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.31" lower_limit="40" upper_limit="301"/>
                    <measurement group_id="O2" value="77.97" lower_limit="31" upper_limit="197"/>
                    <measurement group_id="O3" value="126.89" lower_limit="48" upper_limit="333"/>
                    <measurement group_id="O4" value="188.63" lower_limit="65" upper_limit="549"/>
                    <measurement group_id="O5" value="1.90" lower_limit="0.38" upper_limit="9.44"/>
                    <measurement group_id="O6" value="2.12" lower_limit="0.93" upper_limit="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.19" lower_limit="33" upper_limit="208"/>
                    <measurement group_id="O2" value="60.01" lower_limit="26" upper_limit="138"/>
                    <measurement group_id="O3" value="87.40" lower_limit="37" upper_limit="209"/>
                    <measurement group_id="O4" value="169.45" lower_limit="65" upper_limit="444"/>
                    <measurement group_id="O5" value="1.92" lower_limit="0.45" upper_limit="8.16"/>
                    <measurement group_id="O6" value="2.52" lower_limit="1.20" upper_limit="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ</title>
        <description>The Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in subjects with prevaccination serotype-specific GBS antibody equal or greater than LLQ were estimated for at Day 1, Day 31 and Day 61.</description>
        <time_frame>At Day 1, Day 31 and Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ</title>
          <description>The Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in subjects with prevaccination serotype-specific GBS antibody equal or greater than LLQ were estimated for at Day 1, Day 31 and Day 61.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype Ia - Day 1 (V98_06E1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.06" lower_limit="23" upper_limit="178"/>
                    <measurement group_id="O2" value="98.43" lower_limit="21" upper_limit="469"/>
                    <measurement group_id="O3" value="29.83" lower_limit="9.89" upper_limit="90"/>
                    <measurement group_id="O4" value="39.57" lower_limit="5.84" upper_limit="268"/>
                    <measurement group_id="O5" value="5.76" lower_limit="0.85" upper_limit="39"/>
                    <measurement group_id="O6" value="2.54" lower_limit="0.76" upper_limit="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia - Day 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.91" lower_limit="71" upper_limit="234"/>
                    <measurement group_id="O2" value="196.32" lower_limit="85" upper_limit="456"/>
                    <measurement group_id="O3" value="156.26" lower_limit="86" upper_limit="284"/>
                    <measurement group_id="O4" value="85.63" lower_limit="31" upper_limit="240"/>
                    <measurement group_id="O5" value="177.38" lower_limit="63" upper_limit="498"/>
                    <measurement group_id="O6" value="161.99" lower_limit="84" upper_limit="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype Ia - Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.78" lower_limit="57" upper_limit="222"/>
                    <measurement group_id="O2" value="197.67" lower_limit="76" upper_limit="515"/>
                    <measurement group_id="O3" value="107.57" lower_limit="55" upper_limit="212"/>
                    <measurement group_id="O4" value="93.02" lower_limit="29" upper_limit="300"/>
                    <measurement group_id="O5" value="151.27" lower_limit="47" upper_limit="488"/>
                    <measurement group_id="O6" value="131.48" lower_limit="63" upper_limit="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentrations of GBS Serotype Ib in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ</title>
        <description>The Geometric Mean Antibody Concentrations of GBS Serotype Ib in subjects with prevaccination serotype-specific GBS antibody equal or greater than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
        <time_frame>At Day 1, Day 31 and Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations of GBS Serotype Ib in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ</title>
          <description>The Geometric Mean Antibody Concentrations of GBS Serotype Ib in subjects with prevaccination serotype-specific GBS antibody equal or greater than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" lower_limit="0.56" upper_limit="6.85"/>
                    <measurement group_id="O2" value="0.52" lower_limit="0.17" upper_limit="1.60"/>
                    <measurement group_id="O3" value="3.42" lower_limit="0.28" upper_limit="42"/>
                    <measurement group_id="O4" value="3.12" lower_limit="0.53" upper_limit="18"/>
                    <measurement group_id="O5" value="0.82" lower_limit="0.067" upper_limit="10"/>
                    <measurement group_id="O6" value="1.92" lower_limit="0.63" upper_limit="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.34" lower_limit="90" upper_limit="917"/>
                    <measurement group_id="O2" value="121.26" lower_limit="44" upper_limit="333"/>
                    <measurement group_id="O3" value="373.02" lower_limit="48" upper_limit="2877"/>
                    <measurement group_id="O4" value="338.80" lower_limit="78" upper_limit="1469"/>
                    <measurement group_id="O5" value="557.46" lower_limit="75" upper_limit="4142"/>
                    <measurement group_id="O6" value="557.03" lower_limit="225" upper_limit="1379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.26" lower_limit="72" upper_limit="726"/>
                    <measurement group_id="O2" value="118.94" lower_limit="43" upper_limit="326"/>
                    <measurement group_id="O3" value="367.26" lower_limit="48" upper_limit="2818"/>
                    <measurement group_id="O4" value="300.10" lower_limit="69" upper_limit="1296"/>
                    <measurement group_id="O5" value="378.70" lower_limit="51" upper_limit="2800"/>
                    <measurement group_id="O6" value="403.16" lower_limit="163" upper_limit="996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentrations of GBS Serotype III in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ</title>
        <description>The Geometric Mean Antibody Concentrations of GBS Serotype III in subjects with prevaccination serotype-specific GBS antibody equal or greater than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
        <time_frame>At Day 1, Day 31 and Day 61</time_frame>
        <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations of GBS Serotype III in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ</title>
          <description>The Geometric Mean Antibody Concentrations of GBS Serotype III in subjects with prevaccination serotype-specific GBS antibody equal or greater than LLQ were estimated for at Day 1, Day 31 and Day 61. As the singleton ELISA was no longer in use at the time of serotypes Ib and III testing, results for both serotypes were tested using multiplex immunoassay.</description>
          <population>All screened subjects who provided informed consent and baseline screening measurements, received a subject ID, received study vaccine according to the protocol, and parent study vaccine (non-naïve subjects), and provided immunogenicity data at Day 1, Day 31 or Day 61 in this study.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" lower_limit="0.76" upper_limit="37"/>
                    <measurement group_id="O2" value="1.41" lower_limit="0.029" upper_limit="68"/>
                    <measurement group_id="O3" value="1.07" lower_limit="0.15" upper_limit="7.46"/>
                    <measurement group_id="O4" value="0.74" lower_limit="0.015" upper_limit="36"/>
                    <measurement group_id="O6" value="2.79" lower_limit="0.49" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.67" lower_limit="13" upper_limit="2214"/>
                    <measurement group_id="O2" value="270.01" lower_limit="3.46" upper_limit="21064"/>
                    <measurement group_id="O3" value="120.00" lower_limit="13" upper_limit="1113"/>
                    <measurement group_id="O4" value="149.93" lower_limit="1.81" upper_limit="12454"/>
                    <measurement group_id="O6" value="136.68" lower_limit="19" upper_limit="979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.63" lower_limit="24" upper_limit="1439"/>
                    <measurement group_id="O2" value="231.17" lower_limit="7.12" upper_limit="7509"/>
                    <measurement group_id="O3" value="107.21" lower_limit="18" upper_limit="635"/>
                    <measurement group_id="O4" value="180.29" lower_limit="5.28" upper_limit="6158"/>
                    <measurement group_id="O6" value="116.43" lower_limit="24" upper_limit="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean ELISA Anti-Diphtheria Antibody Concentrations in All Subjects</title>
        <description>Geometric Mean ELISA Anti-Diphtheria Antibody Concentrations (95%CI) in All Subjects at Day 1 Pre-vaccination in the V98_06 study or V98_06E1 for the Naive Group and at Day 61 Post-vaccination in Study V98_06E1. Anti-diphtheria antibody testing was not performed in this study because no diphtheria vaccine was administered in the study and also because data from other Cross Reactive Material(CRM)-based vaccines demonstrate that administration has not resulted in a decline in anti-diphtheria antibody concentrations.</description>
        <time_frame>At Day 1 (V98_06 or V98_06E1) and Day 61</time_frame>
        <population>Anti-diphtheria antibody testing was not performed in this study because no diphtheria vaccine was administered in the study and also because data from other CRM-based vaccines demonstrate that administration has not resulted in a decline in anti-diphtheria antibody concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>GBS NoAdj/GBS NoAdj Group</title>
            <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O2">
            <title>GBS Alum/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O3">
            <title>GBS MF59 Half/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O4">
            <title>GBS MF59 Full/GBS NoAdj Group</title>
            <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O5">
            <title>Placebo/GBS NoAdj Group</title>
            <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
          <group group_id="O6">
            <title>Naive/GBS NoAdj Group</title>
            <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean ELISA Anti-Diphtheria Antibody Concentrations in All Subjects</title>
          <description>Geometric Mean ELISA Anti-Diphtheria Antibody Concentrations (95%CI) in All Subjects at Day 1 Pre-vaccination in the V98_06 study or V98_06E1 for the Naive Group and at Day 61 Post-vaccination in Study V98_06E1. Anti-diphtheria antibody testing was not performed in this study because no diphtheria vaccine was administered in the study and also because data from other Cross Reactive Material(CRM)-based vaccines demonstrate that administration has not resulted in a decline in anti-diphtheria antibody concentrations.</description>
          <population>Anti-diphtheria antibody testing was not performed in this study because no diphtheria vaccine was administered in the study and also because data from other CRM-based vaccines demonstrate that administration has not resulted in a decline in anti-diphtheria antibody concentrations.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs were collected until 7 days after vaccination. Unsolicited AEs were collected from Day 1 to Day 181. SAEs were collected from Day 1 to Day 181.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GBS NoAdj/GBS NoAdj Group</title>
          <description>Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="E2">
          <title>GBS Alum/GBS NoAdj Group</title>
          <description>Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="E3">
          <title>GBS MF59 Half/GBS NoAdj Group</title>
          <description>Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="E4">
          <title>GBS MF59 Full/GBS NoAdj Group</title>
          <description>Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="E5">
          <title>Placebo/GBS NoAdj Group</title>
          <description>Subjects who had received placebo in parent study V98_06 (205468 – NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
        <group group_id="E6">
          <title>Naive/GBS NoAdj Group</title>
          <description>Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E3" events="19" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E4" events="10" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E5" events="12" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" events="23" subjects_affected="11" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="12" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

